Cargando…

Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer

[Image: see text] Disrupting the interplay between programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) is a powerful immunotherapeutic approach to cancer treatment. Herein, spherical nucleic acid (SNA) liposomal nanoparticle conjugates that incorporate a newly designed antis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Liyushang, Callmann, Cassandra E., Dominguez, Donye, Zhang, Bin, Mirkin, Chad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523766/ https://www.ncbi.nlm.nih.gov/pubmed/36188343 http://dx.doi.org/10.1021/acscentsci.2c00717

Ejemplares similares

Impact of Liposomal Spherical Nucleic Acid Structure on Immunotherapeutic Function
por: Callmann, Cassandra E., et al.
Publicado: (2021)

Defining the Design Parameters for in Vivo Enzyme Delivery Through Protein Spherical Nucleic Acids
por: Kusmierz, Caroline D., et al.
Publicado: (2020)

Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy
por: Qin, Lei, et al.
Publicado: (2020)

Spherical nucleic acids for precision medicine
por: Mirkin, Chad A., et al.
Publicado: (2013)

Interplay between programmed death-ligand 1 and non-coding RNAs
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Liposomal Spherical Nucleic Acids
por: Banga, Resham J., et al.
Publicado: (2014)

Spherical Nucleic Acids with Tailored and Active Protein Coronae
por: Zhang, Wuliang, et al.
Publicado: (2019)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Intracellular Fate of Spherical Nucleic Acid Nanoparticle Conjugates
por: Wu, Xiaochen A., et al.
Publicado: (2014)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Design Considerations for RNA Spherical Nucleic Acids (SNAs)
por: Barnaby, Stacey N., et al.
Publicado: (2016)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Nucleic Acid Sensors and Programmed Cell Death
por: Maelfait, Jonathan, et al.
Publicado: (2020)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti–programed death-ligand 1 (Avelumab)
por: Gill, Amanda L., et al.
Publicado: (2016)

Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer
por: Yeh, Yi-Chen, et al.
Publicado: (2022)

Cross-Linked Micellar Spherical Nucleic Acids from Thermoresponsive Templates
por: Banga, Resham J., et al.
Publicado: (2017)

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
por: Chang, Katherine, et al.
Publicado: (2014)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy
por: Castellanos, Emily H., et al.
Publicado: (2017)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
por: Zhao, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6j4047s4263r9n67bc1fv7d632